Dr. Reem Ali is a post-doctoral fellow at Hamad bin Khalifa University. She received her PhD in targeting the base excision repair pathway in breast and ovarian cancers from the University of Nottingham in 2019. She has published key translational studies on PARP inhibitor-induced DNA damage. After joining the Wellcome Centre for Human Genetics, University of Oxford, she expanded her research on the mechanics of PARP inhibitors in endometrial cancers resistant to chemotherapy. She joined Prof Ramotar's Lab at Hamad Bin Khalifa University in 2021 to continue tackling DNA damage in cancer therapies.
Dr. Jennie N Jeyapalan is an Assistant Professor at the Faculty of Medicine and Health Sciences, Faculty of Medicine & Health Sciences, University of Nottingham. She obtained her BSc (Hons) degree in Molecular Biology from the University of Liverpool (1999) and her PhD from the University of Nottingham (2003). She then moved into cancer research as a postdoctoral researcher, where she was involved in projects on alternative telomere maintenance mechanisms (the University of
Leicester, 2003–2008), DNA methylation and microRNAs in paediatric germ cell tumours (the University of Nottingham, 2008–2010) and low-grade astrocytomas (Barts and The London School of Medicine and Dentistry, QMUL, 2010–2016). She
joined the University of Nottingham as an Assistant Professor in 2021. Her area of interest is in endocrine-related cancer, specifically understanding the role of epigenetics in cancer progression and treatment resistance.
Prof. Dr. Dindial Ramotar obtained his PhD in 1989 from McGill University, Department of Biochemistry, and then undertook post-doctoral training at Harvard University, Department of Biochemistry and Molecular Biology. In 1993, he was appointed as an assistant professor at Laval University, Department of Pharmacology, Quebec City, Canada, and in 1997, he was recruited by the University of Montreal, Department of Medicine. In 2007, he became a full professor, and after 23 years of service in Montreal, he moved to Hamad Bin Khalifa University in 2019. During his entire career in Canada, he consistently maintained three active research funding programmes from national granting agencies, including the Canadian Institute of Health Research and the National Cancer Institute of Canada. He has trained over 60 graduate students and post-doctoral fellows and published over 135 peer-reviewed articles. His research programme focuses on (i) drug transport mechanisms for enhancing cancer treatment and (ii) genetic alteration, which affects genomic stability.
